"The
Report Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E
Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Global
Markets Directs, Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or
Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1
2016, provides in depth analysis on Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
targeted pipeline therapeutics.
The
report provides comprehensive information on the Myc
Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39),
targeted therapeutics, complete with analysis by indications, stage
of development, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in Myc
Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic
Helix-Loop-Helix Protein 39) targeted therapeutics development and
features dormant and discontinued projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Download Sample copy of this
Report at
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic
Helix-Loop-Helix Protein 39)
-
The report reviews Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc
or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics
under development by companies and universities/research institutes
based on information derived from company and industry-specific
sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
targeted therapeutics and enlists all their major and minor projects
-
The report assesses Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc
or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics
based on mechanism of action (MoA), route of administration (RoA) and
molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Myc
Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic
Helix-Loop-Helix Protein 39) targeted therapeutics
Reasons to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic
Helix-Loop-Helix Protein 39)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding Myc
Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic
Helix-Loop-Helix Protein 39) development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Read our latest Press
Release at http://www.marketresearchreports.biz/pressreleases
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report
Coverage 5
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
Overview 6
Therapeutics Development 7
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Products under Development by Stage of Development 7
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Products under Development by Therapy Area 8
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Products under Development by Indication 9
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Products under Development by Companies 12
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Products under Development by Universities/Institutes 14
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Therapeutics Assessment 16
Assessment by
Monotherapy/Combination Products 16
Assessment by Mechanism of
Action 17
Assessment by Route of
Administration 18
Assessment by Molecule Type 19
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Companies Involved in Therapeutics Development 21
Dicerna Pharmaceuticals, Inc.
21
Phylogica Limited 22
Sorrento Therapeutics, Inc. 23
Myc Proto-Oncogene Protein
(Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) -
Drug Profiles 24
DCRM-1711 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
JY-3094 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment